181817-14-1

Usage

Uses

Used in Pharmaceutical Development:
(2S,3R)-2-((((9H-Fluoren-9-yl)Methoxy)carbonyl)aMino)-3-acetoxybutanoic acid is used as a building block in the synthesis of pharmaceutical drugs for its unique structural components, which may contribute to the development of novel therapeutic agents with specific biological activities.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (2S,3R)-2-((((9H-Fluoren-9-yl)Methoxy)carbonyl)aMino)-3-acetoxybutanoic acid serves as a subject of study to explore its properties, interactions with biological targets, and potential applications in drug discovery and design.
Further research and analysis are essential to fully understand the capabilities and optimal uses of this chemical in various applications, particularly in the pharmaceutical industry where its unique structure may offer advantages in the creation of new medicines.

Upstream product

• 31077-89-1 1,3,4,6-tetra-O-acetyl-2-deoxy-2-fluoro-β-D-glucopyranose 
• 73731-37-0 Fmoc-Thr-OH 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 17012-42-9 O-acetyl-L-threonine 

Downstream Products

• 17012-42-9 O-acetyl-L-threonine 
• 252049-06-2 N-Fmoc-N-methyl-L-threonine 
• 1353654-66-6 (2S,3R)-benzyl 2-methylamino-3-((triisopropylsilyl)oxy)butanoate 
• 1353654-76-8 (5S)-4-(benzyloxy)-1-methyl-5-{(1R)-1-[(triisopropylsilyl)oxy]ethyl}-1H-pyrrol-2(5H)-one 

Relevant academic research and scientific papers

Synthesis, stereochemical assignment, and bioactivity of the Penicillium metabolites penicillenols B1 and B2

The Penicillium metabolites penicillenols B1 and B2 were synthesised for the first time by elimination of a mesylated penicillenol A precursor as obtained from an l-threonine derived tetramic acid. The (Z,S)- and (E,S)-configured diastereomers were identical to the natural compounds as to NMR spectra and optical rotations. Both isomers showed antiproliferative effects against cancer and endothelial cell lines and penicillenol B1 was also notably antibiotic against Staphylococcus aureus.

Utility of 1,3,4,6-tetra-O-acetyl-2-deoxy-2-[18F] fluoroglucopyranoside for no-carrier-added18F-glycosylation of amino acids

A radiochemical method for the 18F-glycosylation of amino acid side chains was developed starting from peracetylated 2-deoxy-2-[ 18F]fluoroglucopyranoside (TA-[18F]FDG). O-(2-deoxy-2-[18F]fluoro-D-glucopyranosyl)-L-serine and the corresponding threonyl compound were obtained in a radiochemical yield of 25% and 12% (related to [18F]fluoride), respectively, after Zemplen deprotection within a total reaction time of 90 min. The anomeric configuration of the corresponding 19F-substituted compounds revealed preferential α-stereoselectivity. The 18F- glycosylation method using TA-[18F]FDG is compatible with the short half-life of fluorine-18 and combines glycosylation and 18F-labelling of a target compound within a single reaction step. TA-[18F]FDG is a promising 18F-labelled prosthetic group and could be adapted to 18F-labelling of bioactive peptides to study their pharmacokinetics using positron emission tomography (PET). Copyright